Product name: Avanafil

Cas NO: 330784-47-9

M.F: C23H26ClN7O3

M.W:483.95

Capacity: 500KG/M

UsageSexual Enhancement

INQUIRY NOW

■ Description


Avanafil is a highly selective oral phosphodiesterase 5 inhibitor. Phase I, II, and III clinical trials have shown that compared with other chemicalbook phosphodiesterase 5 inhibitors, avanafil has the characteristics of rapid onset, short duration of action, fewer adverse reactions, and good clinical efficacy and safety in the treatment of erectile dysfunction.

Avanafil is a PDE5 inhibitor that was approved by the FDA on April 27, 2012 for the treatment of erectile dysfunction. Avanafil works by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum. Other similar drugs are sildenafil, tadalafil, and vardenafil. The advantage of avanafil is that it has a very rapid onset of action compared to other PDE5 inhibitors. It is rapidly absorbed, reaching maximum serum concentrations in about thirty to forty-five minutes. About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.

■ Message

SUBMIT